Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Rating of “Moderate Buy” from Analysts

Allogene Therapeutics, Inc. (NASDAQ:ALLOGet Free Report) has earned an average rating of “Moderate Buy” from the twelve research firms that are presently covering the company, reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $16.35.

Several equities analysts have issued reports on ALLO shares. HC Wainwright reaffirmed a “buy” rating and set a $23.00 price objective on shares of Allogene Therapeutics in a report on Monday, August 7th. Truist Financial dropped their price target on Allogene Therapeutics from $20.00 to $18.00 in a research note on Wednesday, July 12th. Stifel Nicolaus reduced their price objective on Allogene Therapeutics from $8.00 to $7.50 in a research note on Thursday, May 4th. Oppenheimer restated an “outperform” rating and set a $28.00 target price on shares of Allogene Therapeutics in a research report on Thursday, August 3rd. Finally, JMP Securities cut their target price on shares of Allogene Therapeutics from $19.00 to $15.00 in a report on Friday, May 5th.

Read Our Latest Research Report on ALLO

Insider Transactions at Allogene Therapeutics

In related news, Director Stephen Mayo sold 10,000 shares of the firm’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $4.29, for a total value of $42,900.00. Following the completion of the sale, the director now owns 25,328 shares in the company, valued at $108,657.12. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 27.40% of the company’s stock.

Hedge Funds Weigh In On Allogene Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ALLO. Penserra Capital Management LLC acquired a new position in Allogene Therapeutics during the first quarter worth $66,000. Great West Life Assurance Co. Can raised its stake in shares of Allogene Therapeutics by 26.1% during the 1st quarter. Great West Life Assurance Co. Can now owns 8,827 shares of the company’s stock worth $43,000 after buying an additional 1,826 shares during the last quarter. CI Investments Inc. boosted its position in shares of Allogene Therapeutics by 341.1% in the 4th quarter. CI Investments Inc. now owns 9,002 shares of the company’s stock worth $57,000 after buying an additional 6,961 shares in the last quarter. Nordwand Advisors LLC purchased a new stake in shares of Allogene Therapeutics in the 4th quarter worth about $60,000. Finally, Centaurus Financial Inc. acquired a new stake in Allogene Therapeutics in the 1st quarter valued at about $49,000. 78.51% of the stock is owned by institutional investors and hedge funds.

Allogene Therapeutics Stock Up 3.1 %

Shares of ALLO opened at $3.96 on Thursday. The company has a market capitalization of $663.81 million, a price-to-earnings ratio of -1.62 and a beta of 0.74. Allogene Therapeutics has a 52-week low of $3.70 and a 52-week high of $15.56. The stock has a 50 day moving average price of $4.68 and a 200 day moving average price of $5.31.

Allogene Therapeutics (NASDAQ:ALLOGet Free Report) last issued its earnings results on Wednesday, August 2nd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.06. Allogene Therapeutics had a negative net margin of 184,733.34% and a negative return on equity of 54.13%. The business had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.01 million. During the same quarter in the prior year, the business posted ($0.52) EPS. The company’s revenue for the quarter was down 48.8% on a year-over-year basis. On average, equities analysts anticipate that Allogene Therapeutics will post -2.25 EPS for the current fiscal year.

Allogene Therapeutics Company Profile

(Get Free Report

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.

See Also

Analyst Recommendations for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with's FREE daily email newsletter.